Topical rapamycin reduces tumor growth in mice with tuberous sclerosis
Author Information
Author(s): Aubrey Rauktys, Nancy Lee, Laifong Lee, Sandra L Dabora
Primary Institution: Brigham & Women's Hospital
Hypothesis
Topical rapamycin can inhibit tumor growth in a mouse model of tuberous sclerosis complex.
Conclusion
Topical rapamycin inhibits TSC-related tumor growth and could lead to new treatments for skin lesions associated with TSC.
Supporting Evidence
- Topical rapamycin improved survival in treated mice compared to vehicle control.
- Tumor growth was significantly reduced in mice treated with topical rapamycin.
- Systemic drug levels were achieved within the therapeutic range after topical application.
Takeaway
This study found that putting a cream with rapamycin on mice helped shrink their tumors, which could help people with skin problems from a disease called tuberous sclerosis.
Methodology
Nude mice were treated with different concentrations of topical rapamycin and compared to injected rapamycin and a vehicle control.
Limitations
The study was conducted in mice, which may not fully represent human responses to topical rapamycin.
Participant Demographics
Nude mice (strain CD-1nuBR, up to 6 weeks old)
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website